文献速递肿瘤 PET/CT骨显像与常规 SPECT

骨盆骨髓弥漫性[18F]-FDG摄取指数与PET骨骼模式同多发性骨髓瘤预后标志物、浆细胞形态及治疗反应的相关性

A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-10-25

该前瞻性研究纳入90例多发性骨髓瘤患者(初诊60例,复发/难治30例),计算骨盆/肝脏SUVmax比值并与预后标志物、克隆浆细胞形态及治疗反应进行相关性分析。结果显示该比值与浆细胞分化程度、骨髓浸润率、β2微球蛋白、血清铁蛋白、ISS及修订版ISS相关,切点1.1对弥漫性骨髓受累具有高特异性(99%)和高敏感性(76%)。PET骨骼模式及局灶病变数量亦与预后和治疗反应相关。

要点

  • 骨盆/肝脏SUVmax比值与克隆浆细胞分化程度及多项骨髓瘤预后标志物显著相关。
  • 切点1.1诊断弥漫性骨髓受累的AUC为0.94,特异性99%,敏感性76%。
  • ≥10个局灶病变负向预测总体治疗反应(P<0.05;OR 4.8)。

核心结论

  • 克隆浆细胞形态及与骨髓瘤生物学相关的标志物同骨盆/肝脏SUVmax比值相关,该比值或可作为骨髓评估和疾病预后的替代标志物。
  • PET骨骼模式与骨髓瘤预后特征及治疗反应率相关。

研究设计与样本

  • 前瞻性分析90例多发性骨髓瘤患者的[18F]-FDG PET/CT,其中初诊60例、复发/难治30例。
  • 计算骨盆/肝脏SUVmax比值,并与已知骨髓瘤预后参数、克隆浆细胞形态(良好分化 vs. 低/中分化)及治疗反应进行相关性分析。

主要发现

  • 良好分化组克隆浆细胞的骨盆/肝脏SUVmax比值显著低于中/低分化组(p < 0.001)。
  • 骨盆/肝脏SUVmax比值与骨髓浸润率、β2微球蛋白、血清铁蛋白、国际分期系统(ISS)及修订版ISS呈正相关,与血红蛋白无显著相关性。
  • 混合型模式和附件受累与不良预后特征相关,正常模式(占30%患者)与良好预后特征相关。
  • 存在≥10个局灶病变负向预测总体反应(p < 0.05;OR 4.8)。
  • CT组件提高了PET的诊断性能。

关键数值与推荐

  • 骨盆/肝脏SUVmax比值切点1.1诊断弥漫性骨髓受累的AUC为0.94(p < 0.001),特异性99%,敏感性76%。
  • 正常PET骨骼模式见于30%的患者。
  • ≥10个局灶病变与总体反应负相关(p < 0.05;OR 4.8)。

临床怎么用

  • 骨盆/肝脏SUVmax比值可作为评估骨髓弥漫性受累和疾病预后的半定量参考指标。
  • PET骨骼模式(混合型、附件受累、局灶病变数量)有助于提示预后及预测治疗反应。
  • CT组件可提升PET的诊断效能,判读时应结合CT信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The investigation of a semi-quantitative index in the pelvis to assess for diffuse bone marrow (BM) [18F]-FDG uptake and the investigation of PET skeletal patterns in multiple myeloma (MM) patients, in accordance with prognostic markers, clonal plasma cell (cPC) morphology, and response to therapy. METHODS: We prospectively analyzed [18F]-FDG PET/CT in 90 MM patients (newly diagnosed, 60; relapsed/refractory, 30). Among other PET/CT parameters, we calculated the ratio SUVmax pelvis/liver and examined for correlations with known MM prognostic parameters, cPC morphology (good vs. low/intermediate differentiation), and response to therapy. RESULTS: SUVmax pelvis/liver ratio was significantly lower for the group of good differentiation vs. intermediate/low differentiation cPCs (p < 0.001) and showed a positive correlation with BM infiltration rate, β2 microglobulin, serum ferritin, international staging system (ISS), and revised ISS; no significant correlation was found with hemoglobin. A cutoff value of 1.1 showed an excellent specificity (99%) and high sensitivity (76%) for diffuse BM involvement (AUC 0.94; p < 0.001). Mixed pattern and appendicular involvement correlated with poor prognostic features while normal pattern, found in 30% of patients, correlated with good prognostic features. Presence of ≥ 10 focal lesions negatively predicted for overall response (p < 0.05; OR 4.8). The CT component improved the diagnostic performance of PET. CONCLUSION: This study showed, for the first time, that cPC morphology and markers related with MM biology, correlate with SUVmax pelvis/liver index, which could be used as a surrogate marker for BM assessment and disease prognosis; PET patterns correlate with MM prognostic features and response rates.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Paschali A, Panagiotidis E, Triantafyllou T, et al. A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy. Eur J Nucl Med Mol Imaging. 2020. PMID: 33099659. doi:10.1007/s00259-020-05078-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。